- NCIt
- C27825
Loading cancer entity…
Loading cancer entity…
Clinical trials
23 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01473784 | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | recruiting | N/A | 600 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2026 |
| clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01586767 | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy | unknown | N/A | 45 | Massachusetts General HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01164566 | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy | terminated | N/A | 6 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer | terminated | N/A | 7 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01155609 | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer | completed | N/A | 10 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00023959 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT01637194 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | completed | Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials